semaglutide and beta blockers Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Why cardiologists may prescribe semaglutide

Other risk factors that may increase vulnerability include: Long duration of diabetes (typically more than 10 years) Poor glycaemic control prior to starting GLP-1 therapy (HbA1c significantly above target) Rapid reduction in HbA1c (a drop of more than 2 percentage points [22 mmol/mol] within 36 months) Concurrent hypertension , especially if poorly controlled Diabetic kidney disease (nephropathy), which often correlates with retinopathy severity Previous history of retinal treatment (laser photocoagulation or intravitreal injections) People with type 2 diabetes but no retinopathy appear to have minimal risk of retinopathy progression based on current evidence

When evaluating providers, focus on five factors

Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis

Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy